ジェネリック注射剤市場：製品、タイプ、投与経路、容器、用途、流通チャネル別-2025-2030年世界予測

ジェネリック注射剤市場は、2023年に331億2,000万米ドルと評価され、2024年には365億8,000万米ドルに達すると予測され、CAGR 10.64％で成長し、2030年には672億2,000万米ドルに達すると予測されています。

ジェネリック注射剤市場には、ブランド注射剤と生物学的に同等であるが、一般名で販売される医薬品が含まれます。これらの製品は、費用対効果、必要不可欠な医薬品へのアクセス、医療費削減への貢献により、世界の病院、クリニック、外来患者施設にとって不可欠なものとなっています。医療制度は、逼迫する予算に適応する方法を絶え間なく模索しており、ジェネリック注射剤の活用はこの目標を達成する上で重要な役割を果たしています。この市場の重要な成長促進要因は、糖尿病やがんなどの慢性疾患の蔓延が拡大していることであり、治療に注射剤を頻繁に使用する必要があります。加えて、規制状況、特に特許の崖という形での支援が、市場拡大に有利な状況をもたらしています。しかし、潜在的な課題としては、規制当局の厳しい承認プロセス、価格圧力、製造の複雑さなどがあり、これらは迅速な市場参入を妨げる可能性があります。さらに、サプライチェーンの途絶や、製造品質基準に関連する高コストに関する問題も制約となります。とはいえ、医療インフラが整備されつつあり、安価な医薬品へのアクセスが最優先事項となりつつある新興国市場での需要拡大にはチャンスがあります。企業は、現地に根ざした製造ユニットや提携に投資することで、この動向を活用することができます。注射針を使わない注射剤やプレフィルドシリンジなど、ドラッグデリバリー・システムに焦点を当てたイノベーションは、患者のコンプライアンスを向上させ、新たな消費者層を開拓することができます。生物製剤とバイオシミラーもまた、複雑な治療法を低コストで提供できる可能性があることから、技術革新の有望分野として浮上しています。市場競争は激しく、大小の製薬会社が多数存在するのが特徴であるため、研究開発に戦略的に注力し、ヘルスケアプロバイダーと提携することで、事業の成長を促進することができます。全体として、より持続可能なヘルスケアソリューションの推進は、ジェネリック注射剤を推進し、世界・ヘルス戦略において不可欠な存在であり続けることの必要性を強調しています。

市場力学：急速に進化するジェネリック注射剤市場の主要市場インサイトを公開

ジェネリック注射剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と費用対効果の高い医薬品へのニーズ
  • 特許切れの増加とジェネリック医薬品の採用重視
  • ジェネリック医薬品と注射剤に対する政府の好意的な承認
• 市場抑制要因
  • 患者や医師によるブランド薬志向
• 市場機会
  • ジェネリック注射薬に関する継続的な研究開発活動
  • ジェネリック注射剤を製造するための戦略的な長期パートナーシップ
• 市場の課題
  • 注射剤の品質と製造のばらつきに関する懸念

ポーターのファイブフォース：ジェネリック注射剤市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ジェネリック注射剤市場における外部からの影響の把握

外部マクロ環境要因は、ジェネリック注射剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ジェネリック注射剤市場における競合情勢の把握

ジェネリック注射剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスジェネリック注射剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ジェネリック注射剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ジェネリック注射剤市場における成功への道筋を描く

ジェネリック注射剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と費用対効果の高い医薬品の必要性
    • 特許切れの増加とジェネリック医薬品の導入の重視
    • ジェネリック医薬品と注射剤に対する政府の好意的な承認
  • 抑制要因
    • 患者と医師によるブランド医薬品の好み
  • 機会
    • ジェネリック注射薬に関連する進行中の研究開発活動
    • 製造のための戦略的長期パートナーシップジェネリック注射剤
  • 課題
    • 注射剤の品質と製造のばらつきに関する懸念
• 市場セグメンテーション分析
  • 製品：入手しやすさと親しみやすさから、さまざまな治療領域で低分子注射剤の消費が増加
  • タイプ：活況を呈する経済のダイナミックな成長を探るジェネリック注射剤市場
  • 応用：長期的かつ持続可能な薬剤費を必要とする心臓病学および腫瘍学におけるジェネリック注射剤の大きな利点
  • 流通チャネル：利便性と競争力のある価格を提供するオンラインストアの好感度が上昇
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ジェネリック注射剤市場：製品別

• 高分子注射剤
• 低分子注射剤

第7章 ジェネリック注射剤市場：タイプ別

• 血液因子
• 化学療法剤
• サイトカイン
• インスリン
• モノクローナル抗体
• ペプチド抗生物質
• ペプチドホルモン
• ワクチン

第8章 ジェネリック注射剤市場：投与経路別

• 筋肉内（IM）
• 静脈内（IV）
• 皮下（SC）

第9章 ジェネリック注射剤市場：容器別

• アンプル
• プレフィルドシリンジ
• プレミックス
• バイアル

第10章 ジェネリック注射剤市場：用途別

• 血液疾患
• 心臓病学
• 糖尿病
• ホルモン障害
• 免疫学
• 腫瘍学
• 疼痛管理

第11章 ジェネリック注射剤市場：流通チャネル別

• 病院薬局
• オンライン処方箋販売店
• 小売薬局

第12章 南北アメリカのジェネリック注射剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のジェネリック注射剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのジェネリック注射剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • クーパー・コンシューマー・ヘルスによるビアトリス社のOTC事業の買収
  • テバ、糖尿病治療へのアクセス向上のため、FDA承認の安価なジェネリック医薬品ビクトーザを発売
  • ルピン、FDA承認のガニレリクス酢酸塩注射剤を発売
  • メイシール・ファーマシューティカルズ、ジェネリック注射剤のポートフォリオ拡大を発表
  • エンド社、ノキサフィル（ポサコナゾール）注射剤の初のジェネリック版を発売
• 戦略分析と提言

企業一覧

• Amgen Inc.
• AstraZeneca PLC
• Aurobindo Pharma Limited
• Baxter International Inc.
• Biocon Limited
• Biological E. Limited
• Bristol-Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Endo, Inc.
• Fresenius Kabi AG
• Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Johnson & Johnson Services, Inc.
• Lupin Limited
• Meitheal Pharmaceuticals, Inc.
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Samsung Biologics Co., Ltd.
• Sanofi S.A.
• Somerset Pharma, LLC by Mylan
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc. by Cooper Consumer Health

LIST OF FIGURES

• FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
• FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENERIC INJECTABLES MARKET DYNAMICS
• TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREMIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. CANADA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 63. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. CHINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 95. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. INDIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 101. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 125. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 131. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 143. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. THAILAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. THAILAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 149. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 155. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. DENMARK GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. DENMARK GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 168. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. EGYPT GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. EGYPT GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 174. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FINLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. FINLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 180. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. FRANCE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 186. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. GERMANY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 192. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 198. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. ITALY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. ITALY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 204. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 210. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 216. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. NORWAY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. NORWAY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 222. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. POLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. POLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 228. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. QATAR GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. QATAR GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 234. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 239. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 240. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 246. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SPAIN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. SPAIN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 258. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 264. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 270. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. TURKEY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 275. TURKEY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 276. TURKEY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. TURKEY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 286. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
• TABLE 288. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 290. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 291. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

The Generic Injectables Market was valued at USD 33.12 billion in 2023, expected to reach USD 36.58 billion in 2024, and is projected to grow at a CAGR of 10.64%, to USD 67.22 billion by 2030.

The market for generic injectables encompasses pharmaceutical products that are bioequivalent to branded injectables but are sold under their generic names. These products are critical due to their cost-effectiveness, access to essential medications, and contribution to reduced healthcare expenditure, making them essential for hospitals, clinics, and outpatient facilities globally. Health systems relentlessly seek ways to adapt to tightening budgets, and the utilization of generic injectables plays a crucial role in achieving this goal. A significant growth driver in this market is the increasing prevalence of chronic diseases, such as diabetes and cancer, which necessitates frequent use of injectables for treatment. Additionally, regulatory support, particularly in the form of patent cliff opportunities, provides a favorable landscape for market expansion. However, potential challenges include stringent regulatory approval processes, pricing pressures, and manufacturing complexities, which can impede rapid market entry. Furthermore, issues regarding supply chain disruptions and the high costs associated with production quality standards pose limitations. Nonetheless, opportunities arise from the growing demand in emerging markets, where healthcare infrastructure is developing and access to affordable medication is becoming a high priority. Companies can capitalize on this trend by investing in localized manufacturing units and collaborations. Innovations focusing on drug delivery systems-such as needle-free injectables or pre-filled syringes-can enhance patient compliance and open new consumer segments. Biologics and biosimilars are also emerging as promising areas for innovation due to their potential to offer complex therapies at lower costs. As the market is highly competitive, characterized by numerous small and large pharmaceutical companies, maintaining a strategic focus on R&D and forming alliances with healthcare providers can facilitate business growth. Overall, the push for more sustainable healthcare solutions underscores the imperative of advancing generic injectables, ensuring they remain integral in global health strategies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Injectables Market

The Generic Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and need for cost-effective medications
  • Increasing patent expirations and emphasis on adopting generic drugs
  • Favorable government approvals for generic drugs & injectables
• Market Restraints
  • Preference for branded drugs by patients and physicians
• Market Opportunities
  • Ongoing R&D activities associated with generic injectable drugs
  • Strategic long-term partnerships to manufacture generic injectables
• Market Challenges
  • Concerns associated with injectable quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Injectables Market

A detailed market share analysis in the Generic Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Injectables Market

A strategic analysis of the Generic Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo, Inc., Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC by Mylan, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. by Cooper Consumer Health.

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Large Molecule Injectables and Small Molecule Injectables.
• Based on Type, market is studied across Blood Factors, Chemotherapy Agents, Cytokines, Insulin, Monoclonal Antibodies, Peptide Antibiotics, Peptide Hormones, and Vaccines.
• Based on Route of Administration, market is studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).
• Based on Container, market is studied across Ampoules, Prefilled Syringes, Premix, and Vials.
• Based on Application, market is studied across Blood Disorders, Cardiology, Diabetes, Hormonal Disorders, Immunology, Oncology, and Pain Management.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Prescription Stores, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
    • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
    • 5.1.1.3. Favorable government approvals for generic drugs & injectables
  • 5.1.2. Restraints
    • 5.1.2.1. Preference for branded drugs by patients and physicians
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
    • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
  • 5.2.2. Type: Exploring the dynamic growth in the booming generic injectables market
  • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
  • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Generic Injectables Market, by Product

• 6.1. Introduction
• 6.2. Large Molecule Injectables
• 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

• 7.1. Introduction
• 7.2. Blood Factors
• 7.3. Chemotherapy Agents
• 7.4. Cytokines
• 7.5. Insulin
• 7.6. Monoclonal Antibodies
• 7.7. Peptide Antibiotics
• 7.8. Peptide Hormones
• 7.9. Vaccines

8. Generic Injectables Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intramuscular (IM)
• 8.3. Intravenous (IV)
• 8.4. Subcutaneous (SC)

9. Generic Injectables Market, by Container

• 9.1. Introduction
• 9.2. Ampoules
• 9.3. Prefilled Syringes
• 9.4. Premix
• 9.5. Vials

10. Generic Injectables Market, by Application

• 10.1. Introduction
• 10.2. Blood Disorders
• 10.3. Cardiology
• 10.4. Diabetes
• 10.5. Hormonal Disorders
• 10.6. Immunology
• 10.7. Oncology
• 10.8. Pain Management

11. Generic Injectables Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacy
• 11.3. Online Prescription Stores
• 11.4. Retail Pharmacy

12. Americas Generic Injectables Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Generic Injectables Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Generic Injectables Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Cooper Consumer Health's acquisition of Viatris Inc.'s OTC business
  • 15.3.2. Teva launches affordable FDA-approved generic Victoza boosting diabetes care access
  • 15.3.3. Lupin launches FDA-approved Ganirelix Acetate Injection
  • 15.3.4. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
  • 15.3.5. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. AstraZeneca PLC
• 3. Aurobindo Pharma Limited
• 4. Baxter International Inc.
• 5. Biocon Limited
• 6. Biological E. Limited
• 7. Bristol-Myers Squibb Company
• 8. Cipla Limited
• 9. Dr. Reddy's Laboratories Ltd.
• 10. Endo, Inc.
• 11. Fresenius Kabi AG
• 12. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
• 13. GlaxoSmithKline PLC
• 14. Hikma Pharmaceuticals PLC
• 15. Johnson & Johnson Services, Inc.
• 16. Lupin Limited
• 17. Meitheal Pharmaceuticals, Inc.
• 18. Merck & Co. Inc.
• 19. Novartis AG
• 20. Novo Nordisk A/S
• 21. Pfizer Inc.
• 22. Samsung Biologics Co., Ltd.
• 23. Sanofi S.A.
• 24. Somerset Pharma, LLC by Mylan
• 25. Sun Pharmaceutical Industries Ltd.
• 26. Teva Pharmaceutical Industries Ltd.
• 27. Viatris Inc. by Cooper Consumer Health